Core Viewpoint - Eddiecon Holdings (09860.HK) announced the acquisition of 100% of the issued shares of Crown Bioscience International for a total purchase price of $204 million [1] Group 1: Acquisition Details - The buyer is Miramar Lifesciences Limited, a wholly-owned subsidiary of Eddiecon Holdings [1] - The seller is JSR Life Sciences, LLC, a company established under Delaware law [1] - The acquisition agreement was signed on November 13, 2025 [1] Group 2: Target Company Profile - Crown Bioscience International is a company registered in the Cayman Islands and wholly owned by the seller [1] - The target company operates as a global Contract Research Organization (CRO) [1] - Crown Bioscience focuses on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1] - The company collaborates with biotechnology and pharmaceutical companies to accelerate drug development through integrated preclinical, translational, and clinical biomarker services [1]
艾迪康控股(09860.HK)拟收购Crown Bioscience International 100%股权